Biomaterials used during surgery and wound treatment are of increasing importance in modern medical care. In the present study we set out to evaluate the addition of immunomodulatory thrombin-derived host defense peptides to human acellular dermis (hAD, i.e. epiflex ® ).
Introduction
Over the past years, the use of biomaterial implants and tissue transplants has increased in areas of orthopedics, cardiology, ophthalmology, surgery, and dermatology, to name a few of many uses [1] . Biomaterials may include polymers such as polysaccharides or collagen, silicon or nylon matrices, hyaluronic acid and ester films, fibrin-based materials and hydrogels. Materials implanted into the body of human or an animal must be sterile to minimize risk for subsequent infection, and given bacterial presence, potential endotoxins should be controlled. Infection sensitivity and risk for chronic infections are significant biomaterial-associated problems [1] .
The exact mechanisms underlying biomaterial-related infections have only been partly elucidated, mainly with a current focus on adhesion and biofilm formation. However, in the initial contact with blood or tissues, various biomaterials also induce an excessive inflammatory and coagulative response [2] [3] [4] [5] . In this perspective, novel biologically-oriented strategies, providing coatings which comprise multiple features such as control of inflammation and coagulation, and blocking of bacteria and endotoxins should be of value.
Recently, scaffolds derived from xenogenic and allogenic extracellular matrices have been developed for tissue engineering applications including musculoskeletal, cardiovascular, urogenital and integumentary structures [6] . These bioscaffolds are composed of structural and functional proteins that are part of the native mammalian extracellular matrix that provides structure, mechanical properties, anchorage and communication sites for cells, factors of importance for adequate integration and tissue remodeling [7] . Over the past few years, allogenic human acellular dermis (hAD) has been found to have several applications in reconstructive surgery [8, 9] . Concerns have been raised regarding acellular dermal matrices as a separate risk factor for developing surgical-site infection or inflammation [10, 11] . However, current data describe a relatively low rate of infection when sterile hAD is used [12, 13] Antimicrobial peptides (AMP) are important components of innate immunity [14] . AMPs are short, cationic and amphipathic peptides, displaying broad spectrum activity against various microorganisms, such as bacteria, fungi, and viruses [15, 16] . AMPs may also exert roles in modulating various immune responses [17] [18] [19] , motivating the designation host defense peptides (HDP). Research on novel aspects of the innate immune response activated during infection and wounding has demonstrated that proteolytic cascades generate several novel bioactive HDP with antimicrobial and anti-inflammatory activities in vitro and in vivo [20] [21] [22] [23] [24] [25] . In particular, Cterminal peptides of human thrombin are generated in wounds and fibrin in response to infection and inflammation [20] . Considering the functions of these HDPs, and their presence in the endogenous "biomaterial" fibrin, we aimed to develop an hAD matrix coated with such thrombin-derived HDPs and to explore its potential bactericidal and anti-endotoxic characteristics. Therefore, we coated hAD with the thrombin peptides GKY25 and GKY20 and evaluated their in vitro activity against various bacterial strains characteristic for skin wounds, their effects on lipopolysaccharide (LPS)-mediated inflammatory responses, and activation of coagulation-inducing kallikrein.
Materials and Methods

Peptides
The peptides GKY20 (GKYGFYTHVFRLKKWIQKVI), GKY25
(GKYGFYTHVFRLKKWIQKVIDQFGE), and tetramethylrhodamine (TAMRA) labeled GKY25 were synthesized by Biopeptide Co., San Diego, CA. The purity (95%) of these peptides was confirmed by mass spectral analysis (MALDI-ToF Voyager).
Microorganisms
The microorganisms used in the tests for antimicrobial activity were Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213 obtained from the American Type Culture Collection.
Carrier material
Human cell-free (acellular) dermis allograft (epiflex ® , DIZG, Deutsches Institut für Zell-und Gewebeersatz gemeinnützige GmbH) was prepared as described previously [8] . A biopsy punch was used to fabricate discs with a diameter of 4 mm and a thickness of 0.55 ± 0.25 mm to be used as a carrier material for peptides GKY25 and GKY20.
Disc coating
Peptides were solubilized in sterile water and stock solutions were prepared with concentrations of 0.647, 1.62 and 3.24 mM. Each hAD-disc was coated with 10 µl of peptide solution from an appropriate stock solution. After addition of the peptide solution, discs were incubated in a moisture camber for 1 h at room temperature and then freeze dried for 1 h. The final amount of peptide per 4 mm hAD-disc were 6.5, 16.2, 32.4 nmol respectively.
Polyhexamethylenebiguanide (PHMB) coated hAD-discs were prepared by adding 10 µl of 0.1% PHMB (Cosmocil PG Polyhexanide, ARCH UK biocides, United Kingdom) solution to the discs, followed by freeze drying.
Peptide release from discs
To measure the rate at which peptides were released from hAD, peptide-coated discs were incubated in 100 µl of Tris buffer containing NaCl (10 mM Tris, pH 7.4, 0.15 M NaCl) at 37°C under shaking (500 rpm). Aliquots of 10 µl were taken after 1 min, 30 min, 6 hr, and 24 hr.
Peptide activity was measured by a microbiological assay (Radial Diffusion Assay, RDA) using E. coli ATCC 25922. A similar disc without peptide served as control.
Radial diffusion assay
RDA was performed as described previously [26] . Briefly, bacteria were grown to mid- [27] . To quantify the bactericidal activity, serial dilutions of the incubation mixtures were plated on TH agar, followed by incubation at 37°C overnight and the number of cfu was determined. One hundred percent survival was defined as total survival of bacteria in the same buffer and under the same condition in the absence of peptide. The discs were transferred to another TH agar plate to determine the number of viable adherent bacteria on the disc.
NF-κB/AP-1 Assay
NF-κB and AP-1 activation was assessed in THP1-Xblue™-CD14 reporter cells (here denoted THP-1 cells) (InvivoGen, France) according to the company's instructions. In brief, cells were grown in RPMI 1640 with 10% (v/v) heat-inactivated FBS, 1% Anti-Anti (Invitrogen), 100 µg/ml G418, and 200 µg/ml of Zeocin. Cells were centrifuged at 250 × g for 5 min and resuspended at 2×10 6 cells/ml in RPMI supplemented with 10% heat-inactivated serum and 1%
Anti-Anti. Subsequently, 500 µl/well were placed on 24-well plates. Peptide-coated hAD-discs were incubated with 20 ng of E. coli (0111:B4) LPS (Sigma-Aldrich, USA; approximate 500.000 endotoxin units/mg) in 500 µl of RPMI medium at 37°C for 1 h. After incubation the whole mixture including the disc was transferred to 500 µl of THP-1 cells and incubated. After an 18-22 h incubation at 37 °C and 5% CO 2 , activity was determined in 20 µl of supernatant by using 180 µl QUANTI-Blue substrate (InvivoGen). Plates were incubated at 37°C and the level of secreted embryonic alkaline phosphatase (SEAP), an indicator of activation of transcription factors NF-κB and AP-1, was measured after 1-2 h at OD 600 nm.
MTT assay
Sterile filtered MTT (3-(4,5-dimethylthiazolyl)-2,5-diphenyl-tetrazolium bromide; Sigma-Aldrich) solution (5 mg/ml in PBS) was stored protected from light at -20°C until use. 180 µl of THP1 cells were transferred to 96-well plates (Costar) and 20 µl of the MTT solution was added to each well. Plates were incubated for 3 h in CO 2 at 37°C. After incubation the plate was centrifuged at 300 x g for 10 min and MTT containing medium was removed by aspiration. The blue formazan product generated was dissolved by the addition of 100 µl of 100% DMSO (Applichem, Germany) per well. The plates were then gently swirled for 30 min at room temperature to dissolve the precipitate. The absorbance was measured at 550 nm, and results
given represent mean values from triplicate measurements.
Lactate dehydrogenase (LDH) assay
One hundred µl of each of the supernatants from the above experiment were transferred to 96 well plates for determining LDH release. The LDH based TOX-7 kit (Sigma-Aldrich, St Louis, USA) was used for quantification of LDH. Results given represent mean values from triplicate measurements. Results are given as fractional LDH release compared to the positive control consisting of 1% Triton X-100 yielding 100% LDH release.
Whole blood stimulation and cytokine analysis.
Peptide-coated hAD-discs were incubated with 20 ng of E. coli LPS (Sigma) in 500 µl of RPMI medium at 37°C for 1 h. After incubation the whole mixture including the disc was transferred to 500 µl of lepirudin-blood aliquoted in 24-well plates. After 18-20 h incubation, plasma was collected and stored at -20°C. Cytokine release was measured using BioSource CytoSet™ (Invitrogen) according to the manufacturer's instructions.
Hemolysis assay
EDTA-blood was centrifuged at 800 g for 10 min, and plasma and buffy coat were removed. The erythrocytes were washed three times and re-suspended in 5% PBS, pH 7.4. The cells were then incubated (with end-over-end rotation) for 1 h at 37°C in the presence of peptide-coated discs or peptides alone at indicated concentrations. Samples containing 2% Triton X-100 (Sigma-Aldrich) served as positive control. The samples were then centrifuged at 800 g for 10 min. The hemoglobin release was quantified by measuring the absorbance at λ=540 nm. Data are expressed as a percentage of TritonX-100 induced hemolysis.
Chromogenic substrate assay
Bacteria were grown to mid-logarithmic phase in TH medium. The microorganisms were then washed 3 times with 50 mM Tris-HCl (pH 7.5), re-suspended, and diluted to a final concentration of 2 × 10 6 cfu/ml in 50 mM Tris-HCl/50 µM ZnCl 2 buffer. A total of 100 µl of bacteria were incubated with peptide-coated discs for 10 minutes before the addition of 100 µl human citrate plasma. Samples were incubated for 30 minutes at 37°C with shaking. After centrifugation, pellets were washed twice in 50 mM Tris (pH 7.5), re-suspended in 100 µl 50 mM Tris-HCl/50 µM ZnCl 2 buffer containing 2 mM of the chromogenic substrate S-2302 (Chromogenix), and incubated for 30-60 minutes at 37°C. The samples were centrifuged, and the absorbance of the supernatants was measured at λ=405 nm. No endogenous proteolytic activity was measured when S-2303 was incubated with bacteria in the absence of plasma.
Data analysis
Values are shown as mean +/-SD. For statistical evaluation of two experimental groups, the Mann-Whitney U-test was used. To compare more than two groups One-Way or Two-Way ANOVA with Bonferoni post-test were used. All statistical evaluations were performed using the GraphPad Prism software 6.0. with ns>0.05, *p≤0.05, **≤0.01, ***p≤0.001 and ****p≤0.0001.
Results
Antimicrobial peptide release profile of human acellular dermis coated with thrombin peptides
As mentioned above, GKY20 and GKY25, two C-terminal HDPs derived from human thrombin, have broad antimicrobial and immunomodulatory activities [25] . In order to determine antimicrobial effects of functionalized material, hAD-discs coated with increasing amounts of Figure 1A . As observed, the peptides were rapidly released. After 24 hours of incubation, GKY20 released from hAD showed larger inhibition zones than those observed for GKY25. The antimicrobial activity was dose dependent and a minimum of 6.5 nmol of peptide (corresponding to 20 µg GKY25) released during 24 h was required for detecting any antibacterial effects in the system used. For comparison, peptides alone were also tested for their antimicrobial activity ( Figure 1B) . The antimicrobial activity at 0.65, 16.2 and 32.4 nmol was higher for peptides alone when compared to samples containing peptide released from impregnated discs (compare Fig 1 A and B) . This difference suggested a certain amount of peptide binding to the hAD-discs. Therefore, in a separate experiment, the binding and release of Finally, In order to test the stability of the peptides on hAD, the antimicrobial activity of coated discs, stored for 7 days at room temperature, was compared with the activity of newly prepared discs ( Figure 1C ). Notably, there was no significant difference in the peptide release profile, as demonstrated by similar antimicrobial activity against E. coli in RDA.
Antibacterial effects of peptide-coated human acellular dermis
To investigate the antimicrobial efficacy, the peptide-coated hAD-discs were incubated with E. coli in physiological buffer conditions for 2 h. In concordance with the above results, only discs coated with GKY20 or GKY25 displayed antimicrobial activity (Figure 2A ). With 16.2 and 32.4 nmol peptide added, both peptides yielded complete killing of E. coli bacteria. Simultaneously, as presented in figure 2B , the presence of remaining viable adherent bacteria on the discs was investigated by placing the discs on sterile TH agar plates. The control disc was surrounded by bacterial growth. In accordance with the RDA and viable count data shown above, the two peptides inhibited bacterial growth on the discs, particularly at doses at or above 16.2 nmol per disc.
P. aeruginosa and S. aureus are frequently isolated from patients suffering from infected burns as well as chronic wounds [28] . Therefore, using viable count assays as above, the antimicrobial activity of peptide coated discs (32.4 nmol peptide/disc) was determined against these pathogens and compared with the results on E. coli bacteria (Figure 3 ). Both peptides completely eradicated the two Gram-negative bacterial strains E. coli and P. aeruginosa. A large proportion of the Gram-positive S. aureus bacteria population was killed by GKY25 and GKY20 (Figure 3 ). Since it has been shown that AMPs may be inhibited in plasma [29] , we also tested the activity of the peptide coated discs in plasma as well as acute wound fluid. The results showed that the peptides largely retained their antimicrobial activity in these environments (Figure 4 ).
Peptides protect human acellular dermis from degradation by bacteria
Scanning electron microcopy (SEM) images of the hAD-surface with and without peptidecoating, incubated with bacteria for 2 and 24 h are shown in Figure 5 . As seen in the control discs, the surface of the hAD is covered with P. aeruginosa ( Figure 5A ) and S. aureus ( Figure   5B ), and degradation of collagen fibers can be observed (lower panels). hAD supplemented with GKY20 and GKY25 displayed significant bacterial inhibition at the two time points. Destruction of the collagen fibers was not observed.
Endotoxin-blocking effects of peptide-coated human acellular dermis
In addition to killing microbes directly, HDPs derived from thrombin have been shown to inhibit pro-inflammatory responses as well as excessive coagulation [30] . Figure 6A show that discs coated with the two peptides blocked the NF-κB and AP-1 activation in a dose dependent manner. However, complete blocking was only observed for hAD-discs coated with 32.4 nmol of peptide. To determine whether hAD itself could activate the cells, different batches of hAD-discs alone (3 discs from each batch), were incubated with THP-1 cells for 18 h and the NF-κB and AP-1 activation was studied. A minor, and variable activation was observed with different hAD batches ( Figure 6B ), probably reflecting biological variability and material differences, as previously described for other acellular dermal matrices [31] .
Further, as the results in Figure 1A and Supplementary Figure 1 A and B indicated a certain degree of binding of the peptides to hAD, we undertook to investigate whether peptide-coated hAD still retained the anti-endotoxin effects after three repeated washing steps with buffer (10 mM Tris, 0.15 M NaCl, pH 7.4) as well as more extensive washing for 6 h (Supplementary Figure 1C ). Following washing, the discs were incubated with E. coli LPS (10 ng/ml) and later transferred to THP-1 cells to assess NF-κB and AP-1 activation. As seen, the washed discs retained their anti-endotoxin activity in these experimental setup ( Figure 6C , Supplementary Figure 1C ).
Next, we also determined if the peptide-impregnated hAD-discs could inhibit the LPS-induced production of pro-inflammatory cytokines in whole blood. Human blood was stimulated with 10 ng/ml E. coli LPS in the absence and presence of hAD-discs with or without peptides. In accordance with previous data, both peptide-coated discs significantly inhibited the production of the pro-inflammatory cytokines TNF-α, IL12p40, but also the anti-inflammatory cytokine IL-10 ( Figure 6D ). Many antimicrobial peptides may also permeabilize human cells in vitro [32, 33] , effects which often are abrogated after addition of plasma or blood [15] . Therefore, we evaluated the cytocompatibility of these peptides with erythrocytes and the human monocyte THP-1 cell line. As presented in figure 7A a dose-dependent permeation effect on erythrocytes was observed. Compatible with previous reports, the peptide GKY20 was less hemolytic [25] .
Importantly, when the same amount of peptide was incorporated into hAD-discs, no hemolysis was observed ( Figure 7A) , compatible with the observed scavenging of the peptides by the hAD matrix, reducing the amount of free peptide ( Figure 1A , Supplementary Figure 1 A and C).
Further, potential toxicity of peptides towards the human monocytic cell line THP-1 was evaluated using MTT and LDH assays ( Figure 7B and C) in the various indicated conditions. No peptide-mediated toxicity was observed after an incubation time of 18-20 hours (Figure 7B, C) .
In summary, these results suggest that, in line with previous reports [20, 25, 30] , both GKY20 and GKY25 inhibited LPS-induced cellular responses without significantly affecting the cell viability.
Effect of peptide-coated human acellular dermis on contact activation
Previously, it was shown that GKY25 impairs the intrinsic pathway of coagulation in both human and murine plasma [30] . The contact system is initiated on bacterial membranes or negatively charged surfaces such as kaolin. This involves activation of FXII, which in turn activates plasma kallikrein (PK) and leads to FXI activation [34] . Depending on the type of surface, biomaterials may also induce this activation of the coagulation system [35] . Therefore we measured the PK activation at the surface of hAD alone and in combination with bacteria (P.
aeruginosa) in order to mimic the conditions of a bacterial infection at an implantation site. As shown in figure 8 , hAD, when in contact with human plasma activated the contact system. The activation in the presence of bacteria was higher when compared to hAD alone. The decrease in PK activity was found to occur in a dose-dependent manner in the peptide-coated hAD samples ( Figure 8 ). These results thus demonstrated that exposure to hAD alone could induce activation of the coagulation system, that the initiation was increased in presence of bacteria, and that the two HDPs inhibited this activation.
Effects of GKY25 in combination with PHMB
Antiseptics such as polyhexamethylenebiguanide (PHMB) are commonly used in wound care.
We hypothesized that PHMB, by killing bacteria, may lead to the release of proinflammatory endotoxins. In order to investigate whether GKY25 could block these endotoxins, hAD discs coated with GKY25, PHMB or combinations thereof were incubated with E. coli bacteria for 2 h.
Following incubation, cfu were determined. More than 99% of the bacteria were killed by PHMB, GKY25, and PHMB with GKY25 (data not shown). Subsequently, the bacterial suspension including the discs was transferred to THP-1 cells to assess NF-κB and AP-1 activation. As demonstrated in Figure 9 (upper panel), only hAD discs coated with GKY25 alone or in combination with PHMB blocked NF-κB and AP-1 activation. LDH and MTT assays (middle and lower panel), showed that the substances alone or in combination had minor or no permeation effect. These results demonstrate that GKY25 addition to PHMB inhibits the proinflammatory actions of endotoxins released after subjecting bacteria to the antiseptic.
Discussion
Despite several advances in prophylactic measures, infections still remain a significant complication related to biomaterials [1] . A technically successful operation is no guarantee against biomaterial-associated infections. It is estimated that during surgery in a standard operating theater environment, airborne bacterial wound contamination occurs at approximately 270 bacteria/cm 2 [36] , and hence, most likely, sterile implant surgery is not possible. Although recent advancements in airflow and preventative techniques, particularly used in specialized surgery settings, may reduce this airborne contamination, the presence of a perioperative bacterial load, albeit reduced, is still a cause of infections worldwide. It is also notable that bacteria may be released into the wound from deeper layers in the skin [37, 38] . In order to meet this problem, various antimicrobial coatings have been developed, particularly for use in revision surgery, and involving antibiotics released from implant coatings, or device fixation materials, such as antibiotic-loaded bone cements [39] . In other instances silver-impregnated coatings, or coatings that kill bacteria immediately upon adhesion to the coating are used for prevention of implant infection [1] . With respect to inflammation, anti-inflammatory surfaces are of high interest [2, 4] . For example, Nilsson and colleagues showed that a factor H-binding peptide; and an ADP-degrading enzyme; using a PEG linker on both material and cellular surfaces inhibited complement attack [40] . Thierry et al used an approach toward biomimetic surfaces based on the covalent immobilization of a carboxylate terminated PEGylated hyaluronan (HA-PEG) onto plasma functionalized NiTi alloy surfaces [41] . In other developments, synthetic polymer brushes are used as temaplates for further bioengineering of surfaces with enhaced biocompatibility [42] .
In this perspective, the concept presented here, based on a thrombin-derived endogenous peptide, found in fibrin and released in wounds, represents a novel means of providing a new biological and endogenous antimicrobial functionality to an acellular dermal biomaterial. Previous studies on the two prototypic thrombin C-terminal peptides GKY20 and GKY25 demonstrated that these peptides exert a broad spectrum of antimicrobial and immunomodulatory activities that include inhibition of production of multiple pro-inflammatory cytokines, reduction of vascular leakage, blocking of contact activation and tissue factor-mediated pathways of the coagulation system during LPS-induced experimental shock and in animal models of P. aeruginosa sepsis [20, 25, 30] . For both LPS-induced shock and P. aeruginosa-induced sepsis, regulation of excessive cytokine levels is regarded as a relevant therapeutic target, and it is therefore notable that the peptides significantly dampen the pro-inflammatory cytokine response both in vitro and in vivo.
From the perspective of biomaterials however, the impact on cellular responses such as vasodilation, chemotaxis, and (importantly and specifically), local activation of the coagulation and complement systems may also play critical roles in modulating biocompatibility [2-5, 35, 43-46] . The inflammatory responses caused by implanted materials could be major factors leading to complications or degradation [35, 47, 48] . It is of note, that also endogenous biomaterials, such as dermal substitutes, although considered less proinflammatory, may exert some activating effects on monocytes in vitro [31] . In this perspective, the results in this present work indicate that coating with thrombin-derived peptides adds host defense functions to the human acellular dermis per se. Thus, in addition to a bactericidal effect, coating adds functionalities such as LPS-scavenging and reduction of bacteria-induced contact activation to hAD. In both cases, these effects could lead to advantageous inhibition of local inflammatory responses. Furthermore, the finding that the peptides were adsorbed by the hAD indicates that the cationic and amphipathic peptide may interact with the dermal matrix, consisting of collagen, hyaluronic acid, and other matrix components [49] . 
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